表紙
市場調査レポート

前立腺癌:イタリアにおける治療薬の予測と治療分析(〜2020年)

Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020

発行 GlobalData 商品コード 141955
出版日 ページ情報 英文 219 Pages
即納可能
価格
こちらの商品の販売は終了いたしました。
Back to Top
前立腺癌:イタリアにおける治療薬の予測と治療分析(〜2020年) Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020
出版日: 2010年12月01日 ページ情報: 英文 219 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、イタリアにおける前立腺癌治療薬市場の動向と競合、パイプライン分析、参入企業のプロファイル、アンメットニーズ、開発中の薬剤動向などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 疾病の概要

  • 概要
  • 疫学
  • 病因
  • 症状
  • 診断
  • 病理学
  • 治療
  • 治療ガイドライン

第3章 市場の特性

  • イタリア
    • 市場規模
    • 促進因子と障壁
    • 市場影響
    • 予測
    • 薬剤売上
    • 薬価と償還

第4章 競合評価

  • 戦略的競合評価
  • 上市分析と売上予測
  • 製品プロファイル

第5章 パイプライン評価

  • 概要
  • 開発段階別パイプライン分析
  • 作用機序別パイプライン
  • 戦略的パイプライン評価
  • 前立腺癌パイプライン動向
  • 研究開発パートナー
  • 最も有望な薬剤プロファイル
  • 前治験段階
  • 第1相
  • 第2相
  • 第3相

第6章 アンメットニーズと標的製品プロファイル

第7章 戦略的評価

第8章 企業プロファイル

第9章 M&A動向

第10章 専門家の見解

第11章 付録

図表

目次
Product Code: GDHC014DFR

Abstract

Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020

Summary

GlobalData' s pharmaceutical report, “Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the Italian prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the Italian prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the Italian prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized Italian prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales forecasts.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales forecast.
- Analysis of unmet need in the market and target product profiles including opportunity for target products.
- Technology trends analytic framework to assess the strength of the pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
- An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
- Analysis of the current and future market competition in the Italian Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A analysis) which includes M&A deals by size and geography.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market in Italy.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the Italian prostate cancer therapeutics market.
- Understanding the treatment preferences of physicians for each disease state and across treatment flow.
- Accessing market sizing forecasts and quantified growth opportunities in the Italian prostate cancer therapeutics market up to 2020.
- Quantifying the patient population in the Italian to better design product pricing and launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently marketed products.
- Identifying market entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in the market by understanding the strengths and weaknesses of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.
- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
- Track drug sales in the Italian prostate cancer therapeutics market from 2001 to 2020.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the Italian prostate cancer therapeutics market landscape? Identify, understand and capitalize.

Table of Contents

1 Table of contents 3
1.1 List of Tables 6
1.2 List of Figures 7
2 Disease Overview 9
2.1 Overview 9
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 9
2.1.2 Jewett-Whitmore system 10
2.2 Epidemiology 11
2.3 Etiology 11
2.4 Symptoms 11
2.4.1 Localized or Locally Advanced Prostate Cancer 11
2.4.2 Metastatic Prostate Cancer 12
2.5 Diagnosis 12
2.5.1 Digital Rectal Examination 12
2.5.2 Prostate Specific Antigen Test 13
2.5.3 Transrectal Ultrasound 13
2.5.4 Prostate Biopsy 13
2.6 Pathology 14
2.6.1 Grading 14
2.7 Treatment 14
2.7.1 Watchful Waiting 14
2.7.2 Radiation therapy 14
2.7.3 Surgery 15
2.7.4 Hormone therapy 16
2.7.5 Chemotherapy Options 17
2.7.6 Other Treatments Being Studied 17
2.8 Treatment Guidelines 18
3 Market Characterization 19
3.1 Italy 19
3.1.1 Market Size 19
3.1.2 Drivers & Barriers 25
3.1.3 Impact on the Market 27
3.1.4 Forecasts 28
3.1.5 Drug Sales 34
3.1.6 Pricing and Reimbursements 38
4 Competitor Assessment 39
4.1 Strategic Competitor Assessment 39
4.1.1 Overview 39
4.1.2 Benchmarking 39
4.1.3 Current Competitor Assessment 43
4.2 Launch Analysis and Sales Forecasts 45
4.3 Product Profiles 46
4.3.1 Taxotere (docetaxel) 47
4.3.2 Casodex (Bicalutamide) 51
4.3.3 Zoladex (Goserelin) 57
4.3.4 Eligard (leuprolide acetate) 59
4.3.5 Firmagon (degarelix) 64
4.3.6 Novantrone (Mitoxantrone hydrochloride) 66
4.3.7 Emcyt (estramustine) 69
4.3.8 Trelstar (triptorelin) 71
4.3.9 Eulexin 72
4.3.10 Delestrogen 74
4.3.11 Gynodiol 76
4.3.12 Estrace tablet 77
4.3.13 Tace 78
4.3.14 Nilandrone 79
4.3.15 Premarin 80
4.3.16 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol 81
5 Pipeline Assessment 82
5.1 Overview 82
5.2 Pipeline Analysis by Phase of Development 83
5.3 Pipeline by Mechanism of Action 84
5.4 Strategic Pipeline Assessment 85
5.4.1 Technology Trends Analytical Framework 85
5.5 Trends in Prostate Cancer Pipeline 86
5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs 86
5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline 86
5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 87
5.6 Partners in Research and Development 87
5.6.1 Licensing Agreements by Phase of Development 88
5.6.2 Licensing Agreements by Geography 91
5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 91
5.7 Most Promising Drugs’ Profiles 92
5.7.1 Provenge (sipuleucel-T) 94
5.7.2 Jevtana (cabazitaxel) 96
5.7.3 Aflibercept (VEGF Trap) 97
5.7.4 Ipilimumab 100
5.7.5 Abiraterone Acetate (CB7630) 102
5.7.6 Zibotentan (ZD4054) 105
5.7.7 Sprycel (dasatinib) 108
5.7.8 MDV3100 110
5.8 Prostate Cancer Pipeline - Pre-clinical Phase 112
5.9 Prostate Cancer Pipeline - Phase I 114
5.10 Prostate Cancer Pipeline - Phase II 117
5.11 Prostate Cancer Pipeline - Phase III 125
5.12 Key Takeaway 127
6 Unmet Need and Target Product Profile 128
6.1 Unmet Need 130
6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 131
6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 132
6.2 Opportunity for Target Product 132
6.3 Target Product Profile 134
6.3.1 Ideal Characteristics 134
6.3.2 Target Product Description 135
6.4 Key Takeaway 135
7 Strategic Assessment 136
7.1 Key Events Impacting the Future Market 136
7.2 Market Impact Analysis 137
7.3 Future Market Scenario 137
7.4 Company Analysis 139
7.4.1 Market Leadership 139
7.4.2 Future Players in the Market 139
7.5 Key Takeaway 140
8 Company Profiles 141
8.1 Sanofi-aventis 141
8.1.1 Business Description 141
8.1.2 Financial Overview 143
8.1.3 SWOT Analysis 143
8.1.4 Oncology Focus 148
8.2 Pfizer Inc. 149
8.2.1 Business Description 149
8.2.2 Financial Overview 150
8.2.3 SWOT Analysis 150
8.2.4 Oncology Focus 157
8.3 AstraZeneca 159
8.3.1 Business Description 159
8.3.2 Financial Overview 160
8.3.3 SWOT Analysis 161
8.3.4 Oncology Focus 165
8.4 Bristol-Myers Squibb 167
8.4.1 Business Description 167
8.4.2 Financial Overview 168
8.4.3 SWOT Analysis 168
8.4.4 Oncology Focus 174
8.5 Medivation 176
8.5.1 Business Description 176
8.5.2 SWOT Analysis 176
8.5.3 Oncology Focus 179
8.6 Takeda Pharmaceuticals 180
8.6.1 Business Description 180
8.6.2 SWOT Analysis 180
8.7 Dendreon Corporation 182
8.7.1 Business Description 182
8.7.2 SWOT Analysis 182
8.8 Johnson and Johnson 185
8.8.1 Business Description 185
8.8.2 SWOT Analysis 187
8.8.3 Oncology Focus 193
8.9 Auron Healthcare GmbH 194
8.9.1 Business Description 194
8.10 Oncogenex Pharmaceuticals, Inc. 194
8.10.1 Business Description 194
8.11 Agennix AG 194
8.11.1 Business Description 194
8.12 GTx, Inc. 195
8.12.1 Business Description 195
8.13 GlaxoSmithKline plc. 195
8.13.1 Business Description 195
8.13.2 Financial Overview 196
8.13.3 SWOT Analysis 196
8.13.4 Oncology Focus 202
9 M&A Analysis 204
9.1 Key Highlights 204
9.2 Key Deals’ Analysis 206
9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 206
9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 206
9.2.3 Tolmar Holding Acquires QLT USA from QLT 206
9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 206
9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 206
9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 207
9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax 207
9.2.8 GPC Biotech Merges with Agennix 207
9.2.9 Eli Lilly Acquires ImClone 207
9.2.10 BBM Holdings Acquires YM BioSciences 207
9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 208
9.3 M&A Deals by Geography 208
9.4 M&A Deals by Deal Size 209
10 Expert Opinion 210
10.1 Italy 210
11 Appendix 211
11.1 Market Definitions 211
11.2 Abbreviations 211
11.3 Research Methodology 213
11.3.1 Coverage 213
11.3.2 Secondary Research 214
11.3.3 Forecasting 214
11.3.4 Primary Research 217
11.3.5 Expert Panel validation 217
11.3.6 Contact Us 217
11.4 Disclaimer 217
11.5 Sources 218

1.1 List of Tables
Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 10
Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 13
Table 3: Prostate Cancer Therapeutics Market, Italy, Sales Value ($m), 2001-2009 19
Table 4: Prostate Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2001-2009 20
Table 5: Prostate Cancer Therapeutics Market, Italy, Patient Volume (’000s), 2001-2009 22
Table 6: Prostate Cancer Therapeutics Market, Italy, Treatment Usage Patterns (’000s), 2001-2009 23
Table 7: Prostate Cancer Therapeutics Market, Italy, Sales Value ($m), 2009-2020 28
Table 8: Prostate Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2009-2020 29
Table 9: Prostate Cancer Therapeutics Market, Italy, Patient Volume (’000s), 2009-2020 30
Table 10: Prostate Cancer Therapeutics Market, Italy, Treatment Usage Patterns (’000s), 2009-2020 31
Table 11: Prostate Cancer Therapeutics Market, Italy, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2001-2010 35
Table 12: Prostate Cancer Therapeutics Market, Italy, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2011-2020 35
Table 13: Prostate Cancer Therapeutics Market, Italy, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2010 37
Table 14: Prostate Cancer Therapeutics Market, Italy, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2011-2020 37
Table 15: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 40
Table 16: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 41
Table 17: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 42
Table 18: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 52
Table 19: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 60
Table 20: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 61
Table 21: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 62
Table 22: Prostate Cancer, Global, Licensing Agreements, 2009-2010 90
Table 23: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 92
Table 24: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 92
Table 25: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 112
Table 26: Prostate Cancer, Global, Phase I Pipeline, August 2010 114
Table 27: Prostate Cancer, Global, Phase II Pipeline, August 2010 117
Table 28: Prostate Cancer, Global, Phase III Pipeline, August 2010 125
Table 29: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 134
Table 30: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 135
Table 31: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 193
Table 32: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 194
Table 33: Prostate Cancer, Global, M&A Deals by Geography, 2010 204

1.2 List of Figures
Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 18
Figure 2: Prostate Cancer Therapeutics Market, Italy, Sales Value ($m), 2001-2009 19
Figure 3: Prostate Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2001-2009 20
Figure 4: Prostate Cancer Therapeutics Market, Italy, Patient Volume (’000s), 2001-2009 22
Figure 5: Prostate Cancer Therapeutics Market, Italy, Treatment Usage Patterns (’000s), 2001-2009 23
Figure 6: Prostate Cancer Therapeutics Market, Italy, Market Drivers and Restraints, 2009 25
Figure 7: Prostate Cancer Therapeutics Market, Italy, Historical Events Impact on the Market, 2010 27
Figure 8: Prostate Cancer Therapeutics Market, Italy, Sales Value ($m), 2009-2020 28
Figure 9: Prostate Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2009-2020 29
Figure 10: Prostate Cancer Therapeutics Market, Italy, Patient Volume (’000s), 2009-2020 30
Figure 11: Prostate Cancer Therapeutics Market, Italy, Treatment Usage Patterns (’000s), 2009-2020 31
Figure 12: Prostate Cancer Therapeutics Market, Italy, Future Market Drivers and Restraints, 2009-2020 33
Figure 13: Prostate Cancer Therapeutics Market, Italy, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 34
Figure 14: Prostate Cancer Therapeutics Market, Italy, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2020 36
Figure 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 43
Figure 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 44
Figure 17: Prostate Cancer Therapeutics Market, Italy, Sales Forecast by Therapies, 2001-2020 45
Figure 18: Prostate Cancer, Global, Taxotere, Chemical Structure 47
Figure 19: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 49
Figure 20: Prostate Cancer, Italy, Taxotere, Sales ($m), 2004-2020 50
Figure 21: Prostate Cancer, Global, Casodex, Chemical Structure 51
Figure 22: Prostate Cancer, Global, Casodex, LCM Activities, 1995-2010 55
Figure 23: Prostate Cancer, Italy, Casodex, Sales ($m), 1995-2020 56
Figure 24: Prostate Cancer, Global, Zoladex, Chemical Structure 57
Figure 25: Prostate Cancer, Italy, Zoladex, Sales Forecast ($m), 1998-2020 58
Figure 26: Prostate Cancer, Global, Eligard , Chemical Structure 59
Figure 27: Prostate Cancer, Italy, Leuprolide (Eligard), Sales Forecast ($m), 2006-2020 63
Figure 28: Prostate Cancer, Global, Firmagon, Chemical Structure 64
Figure 29: Prostate Cancer, Italy, Firmagon, Sales Forecast ($m), 2009-2020 65
Figure 30: Prostate Cancer, Global, Novatrone, Chemical Structure 66
Figure 31: Prostate Cancer, Italy, Mitoxantrone, Sales Forecast ($m), 2001-2020 68
Figure 32: Prostate Cancer, Global, Emcyt, Chemical Structure 69
Figure 33: Prostate Cancer, Italy, Estramustine, Sales Forecast ($m), 2001-2020 70
Figure 34: Prostate Cancer, Global, Trelstar, Chemical Structure 71
Figure 35: Prostate Cancer, Global, Eulexin, Chemical Structure 72
Figure 36: Prostate Cancer, Global, Delestrogen, Chemical Structure 74
Figure 37: Prostate Cancer, Global, Gynodiol, Chemical Structure 76
Figure 38: Prostate Cancer, Global, Estrace, Chemical Structure 77
Figure 39: Prostate Cancer, Global, Tace, Chemical Structure 78
Figure 40: Prostate Cancer, Global, Nilandrone, Chemical Structure 79
Figure 41: Prostate Cancer, Global, Premarin, Chemical Structure 80
Figure 42: Prostate Cancer, Italy, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 81
Figure 43: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 82
Figure 44: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 83
Figure 45: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 84
Figure 46: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 85
Figure 47: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 86
Figure 48: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 88
Figure 49: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 91
Figure 50: Prostate Cancer, Italy, Provenge, Sales Forecast ($m), 2012-2020 95
Figure 51: Prostate Cancer, Italy, Jevtana, Sales Forecast ($m), 2011-2020 97
Figure 52: Prostate Cancer, Global, Aflibercept, Chemical Structure 98
Figure 53: Prostate Cancer, Italy, Aflibercept, Sales Forecast ($m), 2014-2020 99
Figure 54: Prostate Cancer, Italy, Ipilimumab , Sales Forecast ($m), 2014-2020 101
Figure 55: Prostate Cancer, Global, Abiraterone, Chemical Structure 102
Figure 56: Prostate Cancer, Italy, Abiraterone, Sales Forecast ($m), 2013-2020 104
Figure 57: Prostate Cancer, Global, Zibotentan, Chemical Structure 105
Figure 58: Prostate Cancer, Italy, Zibotentan , Sales Forecast ($m), 2013-2020 107
Figure 59: Prostate Cancer, Italy, Sprycel , Sales Forecast ($m), 2013-2020 109
Figure 60: Prostate Cancer, Global, MDV3100, Chemical Structure 110
Figure 61: Prostate Cancer, Italy, MDV3100 , Sales Forecast ($m), 2013-2020 111
Figure 62: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 128
Figure 63: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 129
Figure 64: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 129
Figure 65: Prostate Cancer, Italy, Prostate Cancer, Opportunity and Unmet Need, 2010 130
Figure 66: Prostate Cancer, Italy, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 133
Figure 67: Prostate Cancer, Italy, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 133
Figure 68: Prostate Cancer, Global, Key Events Impacting the Future Market 136
Figure 69: Prostate Cancer, Italy, Implications for Future Market Competition, 2010 137
Figure 70: Prostate Cancer, Global, Future Players in the Market, 2010 139
Figure 71:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 141
Figure 72: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 142
Figure 73: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 143
Figure 74: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 148
Figure 75: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 150
Figure 76: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 157
Figure 77: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 158
Figure 78: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 160
Figure 79: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 161
Figure 80: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 165
Figure 81: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 166
Figure 82: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 166
Figure 83: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 167
Figure 84: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 168
Figure 85: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 174
Figure 86: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 175
Figure 87: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 176
Figure 88: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT Analysis 2010 180
Figure 89: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 182
Figure 90: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 187
Figure 91: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 193
Figure 92: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 196
Figure 93: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 202
Figure 94: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 203
Figure 95: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010 208
Figure 96: Prostate Cancer, Global, M&A Deals by Deal Size, 2010 209
Figure 97: Prostate Cancer, Italy, Key Data Inputs from KOL Interviews, July 2010 210
Figure 99: GlobalData Market Forecasting Model 216

Back to Top